Brief description of the instructions for use of ritexitinib Lao version

Ritexitinib is a targeted treatment drug for severe alopecia areata, suitable for adults and adolescents 12 years old and above. The drug promotes hair growth by modulating the immune system and blocking the pathological mechanisms that cause hair loss. Due to the high price of the original drug, Laos Lucius Company has launched a relatively affordable version of ritexitinib to meet the needs of more patients. This article will briefly introduce the Lao version of the guidelines for the use of ritexitinib to help patients better understand its dosage, administration methods and precautions during use.

The recommended dose of the Lao version of ritexitinib is50 mg once a day, and patients can choose to take it with or without food. When taking, the capsule should be swallowed whole and avoid crushing, chewing or damaging the integrity of the capsule to ensure drug release and absorption. If a dose is accidentally missed, the dose should be taken as soon as possible, but if the next dose is less than 8 hours away, the missed dose should be skipped and the dose should be resumed at the regularly scheduled time. In order to ensure the continuity of treatment, it is recommended that patients maintain regular medication habits to avoid missing doses.

For some special circumstances, special attention should be paid when using ritexitinib. This drug is not recommended for patients with severe hepatic impairment (e.g. Child Pugh class C). In addition, if a temporary interruption of treatment is necessary, it is expected that interruptions shorter than 6 weeks will generally not significantly affect scalp hair regrowth, but it is best to evaluate under the guidance of a doctor. During use, patients known to be allergic to ritexitinib or any of its excipients should refrain from taking this drug to ensure safety.

During the use of rituxitinib, patients should be aware of interactions with other drugs. Many drugs, including prescription drugs, over-the-counter drugs, vitamins, and herbal products, may affect the efficacy of rituxitinib, so it is important to inform your doctor of all other drugs you are taking, especially CYP3A substrates, CYP3A inducers, and CYP1A2 substrates. At the same time, ritixitinib should not be used in combination with other JAK inhibitors, biological immunomodulators, cyclosporine, or other potent immunosuppressants to prevent potential side effects and drug interactions.

Some common side effects that patients may experience while taking ritexitinib include headache, diarrhea, acne, rash, inflammation of the pores (folliculitis), fever, eczema, dizziness, shingles, reduced red blood cell count, and mouth ulcers. If obvious discomfort occurs, you should seek medical treatment immediately to deal with possible problems in a timely manner to ensure your health.

In conclusion, the Lao version of ritexitinib, as an economical treatment option for alopecia areata, brings new hope to patients. However, before use, patients should read the relevant instructions in detail and follow their doctor's recommendations to ensure safety and effectiveness.

References:

https://www.drugs.com/litfulo.html

https://www.drugs.com/search.php?searchterm=LITFULO&sources%5B%5D=professional

xa0